Latest news
Business Update
Kopfwehzentrum Hirslanden joins Priority Access Program
We are happy to welcome the Kopfwehzentrum Hirslanden as an early adopter of our Priority Access Program for migraine patients!
04 December, 2024
Read more
Publication | Tue 01, 2024
Bottneuro publishes Whitepaper
Read more about the technology, our customized Miamind® Neurostimulator and the opportunity the recent registration at Swissmedic and MHRA offers in o...
Business Update | Thu 01, 2024
The MINDSTIM clinical trial officially started!
A new year, another Milestone in Bottneuro’s journey to develop a non-invasive Alzheimer’s Disease therapy. The MINDSTIM clinical trial officially sta...
Business Update | Fri 11, 2023
Miamind® Neurostimulator officially registered with Swissmedic and MHRA
Excellent news for patients. After three years of development, Miamind®, the patient-specific neurostimulator for non-invasive brain stimulation, can...
Events & Conferences | Mon 11, 2023
Bottneuro at MEDICA 2023
Bottneuro is attending the this years MEDICA conference in Düsseldorf, Germany, one of the largest medical B2B trade fairs globally!
Featured news
